Minerva Neurosciences, Inc. Increase (Decrease) in Derivative Liabilities
Minerva Neurosciences, Inc. (NERV) reported Increase (Decrease) in Derivative Liabilities of $117 for the 12-month period ending 2013-12-31, per its 10-K filed 2015-03-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2015-03-26
- Minerva Neurosciences, Inc. increase (decrease) in derivative liabilities for fiscal 2013 was $117.00.
| Period end | Increase (Decrease) in Derivative Liabilities 12 month |
|---|---|
| 2013-12-31 | $117.00 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |